

Frequently asked Questions & Answers about *Emgality*® (galcanezumab)

From 1st June 2021 *Emgality*® (galcanezumab) will be the first PBS-listed CGRP treatment for chronic migraine.

Who can access this treatment?

People with chronic migraine meeting the eligibility criteria set by PBS will be able to access *Emgality*®. For chronic migraine this means:

- ✓ 15 or more headache days per month, with at least 8 days of migraine, over a period of at least 6 months
- ✓ Inadequate response, intolerance or a contraindication to at least three prophylactic migraine medications (preventers)

How much will *Emgality*® cost?

Emgality® will be available for the standard PBS co-payment price, which is usually \$41.30 or \$6.60 for concession holders

Where can I get *Emgality*®?

Emgality® will be available at any pharmacy but in the beginning your local pharmacy may need a day or two to order it in.

Who can prescribe *Emgality*®?

Treatment with *Emgality*® must be initiated by a neurologist who will need an Authority streamline code to write the prescription. Codes will be hopefully be made available by June 1st.

Can I access *Emgality*® on the PBS if I am also having treatment with Botox® through the PBS?

No. Under the current PBS listing, *Emgality*® cannot be prescribed to people who are also receiving botulinum toxin (*Botox*®) at a subsidised cost through the PBS

Can I access *Emgality*® for episodic migraine?

Access to *Emgality*® for people who do not meet the PBS reimbursement criteria for chronic migraine will continue via the Ember program (RRP \$263 per month).